Mast Cells Produce Novel Shorter Forms of Perlecan That Contain Functional Endorepellin

Background: Mast cells modulate events in wound healing. Results: Shorter forms of perlecan are produced by mast cells via proteolytic processing and alternative splicing, which contain domain V and functional endorepellin. Conclusion: The production of these shorter forms modulates endothelial cell adhesion, proliferation, and migration. Significance: Mast cells produce specific forms of perlecan that affect endothelial cell behavior. Mast cells are derived from hematopoietic progenitors that are known to migrate to and reside within connective and mucosal tissues, where they differentiate and respond to various stimuli by releasing pro-inflammatory mediators, including histamine, growth factors, and proteases. This study demonstrated that primary human mast cells as well as the rat and human mast cell lines, RBL-2H3 and HMC-1, produce the heparan sulfate proteoglycan, perlecan, with a molecular mass of 640 kDa as well as smaller molecular mass species of 300 and 130 kDa. Utilizing domain-specific antibodies coupled with N-terminal sequencing, it was confirmed that both forms contained the C-terminal module of the protein core known as endorepellin, which were generated by mast cell-derived proteases. Domain-specific RT-PCR experiments demonstrated that transcripts corresponding to domains I and V, including endorepellin, were present; however, mRNA transcripts corresponding to regions of domain III were not present, suggesting that these cells were capable of producing spliced forms of the protein core. Fractions from mast cell cultures that were enriched for these fragments were shown to bind endothelial cells via the α2β1 integrin and stimulate the migration of cells in “scratch assays,” both activities of which were inhibited by incubation with either anti-endorepellin or anti-perlecan antibodies. This study shows for the first time that mast cells secrete and process the extracellular proteoglycan perlecan into fragments containing the endorepellin C-terminal region that regulate angiogenesis and matrix turnover, which are both key events in wound healing.

[1]  A. Parker,et al.  A Fragment of the LG3 Peptide of Endorepellin Is Present in the Urine of Physically Active Mining Workers: A Potential Marker of Physical Activity , 2012, PloS one.

[2]  C. Perreault,et al.  The Perlecan Fragment LG3 Is a Novel Regulator of Obliterative Remodeling Associated With Allograft Vascular Rejection , 2012, Circulation research.

[3]  L. M. Moir,et al.  Human lung mast cells modulate the functions of airway smooth muscle cells in asthma , 2011, Allergy.

[4]  A. Fertala,et al.  Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents. , 2011, The Journal of clinical investigation.

[5]  K. Sekiguchi,et al.  Endorepellin, the Angiostatic Module of Perlecan, Interacts with Both the α2β1 Integrin and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) , 2011, The Journal of Biological Chemistry.

[6]  Christine Y. Chuang,et al.  Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. , 2010, Biochemistry.

[7]  Y. Durocher,et al.  Epidermal Growth Factor and Perlecan Fragments Produced by Apoptotic Endothelial Cells Co‐Ordinately Activate ERK1/2‐Dependent Antiapoptotic Pathways in Mesenchymal Stem Cells , 2010, Stem cells.

[8]  Michael F Y Ng The role of mast cells in wound healing , 2010, International wound journal.

[9]  S. O. Kolset,et al.  Mast Cell Differentiation and Activation Is Closely Linked to Expression of Genes Coding for the Serglycin Proteoglycan Core Protein and a Distinct Set of Chondroitin Sulfate and Heparin Sulfotransferases1 , 2009, The Journal of Immunology.

[10]  Carsten Ehrhardt,et al.  RBL-2H3 cells are an imprecise model for mast cell mediator release , 2009, Inflammation Research.

[11]  A. Pshezhetsky,et al.  Caspase-3 Activation Triggers Extracellular Cathepsin L Release and Endorepellin Proteolysis* , 2008, Journal of Biological Chemistry.

[12]  A. Pozzi,et al.  Integrin α2β1 Is the Required Receptor for Endorepellin Angiostatic Activity* , 2008, Journal of Biological Chemistry.

[13]  D. Noh,et al.  Identification of circulating endorepellin LG3 fragment: Potential use as a serological biomarker for breast cancer , 2008, Proteomics. Clinical applications.

[14]  J. Hassell,et al.  The core protein of growth plate perlecan binds FGF-18 and alters its mitogenic effect on chondrocytes. , 2007, Archives of biochemistry and biophysics.

[15]  Michael Elkin,et al.  Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis , 2007, Development.

[16]  R. Iozzo,et al.  Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the α2β1-integrin receptor , 2007 .

[17]  L. Hellman,et al.  Serglycin proteoglycan is required for secretory granule integrity in mucosal mast cells. , 2007, The Biochemical journal.

[18]  R. Iozzo,et al.  Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the alpha2beta1-integrin receptor. , 2007, Blood.

[19]  James Melrose,et al.  The Structure, Location, and Function of Perlecan, a Prominent Pericellular Proteoglycan of Fetal, Postnatal, and Mature Hyaline Cartilages* , 2006, Journal of Biological Chemistry.

[20]  A. Theocharis,et al.  Serglycin Constitutively Secreted by Myeloma Plasma Cells Is a Potent Inhibitor of Bone Mineralization in Vitro* , 2006, Journal of Biological Chemistry.

[21]  M. Åbrink,et al.  A role for serglycin proteoglycan in granular retention and processing of mast cell secretory granule components , 2006, The FEBS journal.

[22]  R. Iozzo,et al.  Perlecan Proteolysis Induces an α2β1 Integrin- and Src Family Kinase-dependent Anti-apoptotic Pathway in Fibroblasts in the Absence of Focal Adhesion Kinase Activation* , 2006, Journal of Biological Chemistry.

[23]  T. Koob,et al.  Changes in perlecan during chondrocyte differentiation in the fetal bovine rib growth plate , 2006, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[24]  J. Chan,et al.  Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts , 2005, BMC Cancer.

[25]  Renato V Iozzo,et al.  Heparan sulfate: a complex polymer charged with biological activity. , 2005, Chemical reviews.

[26]  R. Iozzo,et al.  BMP-1/Tolloid-like Metalloproteases Process Endorepellin, the Angiostatic C-terminal Fragment of Perlecan* , 2005, Journal of Biological Chemistry.

[27]  Jocelyn E. Shaw,et al.  SMU-2 and SMU-1, Caenorhabditis elegans Homologs of Mammalian Spliceosome-Associated Proteins RED and fSAP57, Work Together To Affect Splice Site Choice , 2004, Molecular and Cellular Biology.

[28]  Samuel A. Santoro,et al.  Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin , 2004, The Journal of cell biology.

[29]  S. Rennard,et al.  Co-Cultured Human Mast Cells Stimulate Fibroblast-Mediated Contraction of Collagen Gels , 2001, Inflammation.

[30]  R. Diegelmann,et al.  Wound healing: an overview of acute, fibrotic and delayed healing. , 2004, Frontiers in bioscience : a journal and virtual library.

[31]  Shawn M. Sweeney,et al.  Endorepellin, a Novel Inhibitor of Angiogenesis Derived from the C Terminus of Perlecan* , 2003, Journal of Biological Chemistry.

[32]  J. Melrose,et al.  Not All Perlecans Are Created Equal , 2002, The Journal of Biological Chemistry.

[33]  James Melrose,et al.  Electrophoretic, biosensor, and bioactivity analyses of perlecans of different cellular origins , 2001, Proteomics.

[34]  C. Spike,et al.  Analysis of smu-1, a Gene That Regulates the Alternative Splicing of unc-52 Pre-mRNA inCaenorhabditis elegans , 2001, Molecular and Cellular Biology.

[35]  J. Uitto,et al.  The Protein Core of the Proteoglycan Perlecan Binds Specifically to Fibroblast Growth Factor-7* , 2000, The Journal of Biological Chemistry.

[36]  J. Couchman,et al.  Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. , 1999, Biochemical and biophysical research communications.

[37]  D. Moerman,et al.  Complex patterns of alternative splicing mediate the spatial and temporal distribution of perlecan/UNC-52 in Caenorhabditis elegans. , 1999, Molecular biology of the cell.

[38]  R. Iozzo,et al.  Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. , 1999, Matrix biology : journal of the International Society for Matrix Biology.

[39]  M. Artuc,et al.  Mast cells and their mediators in cutaneous wound healing – active participants or innocent bystanders? , 1999, Experimental dermatology.

[40]  S. A. Ibrahim Anterior Cruciate Ligament Reconstruction by Combined Intra-Articular (K. Lambert) and Extra-Articular Iliotibial Band Tenodesis (MacIntosh; Autologous Grafts) , 1999, Medical Principles and Practice.

[41]  J. Uitto,et al.  Structural and Functional Characterization of the Human Perlecan Gene Promoter , 1997, The Journal of Biological Chemistry.

[42]  M. Kunimatsu,et al.  Purification and characterization of perlecan fragment in urine of end-stage renal failure patients. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[43]  U. Greferath,et al.  A proteoglycan that activates fibroblast growth factors during early neuronal development is a perlecan variant. , 1996, Development.

[44]  D. Moerman,et al.  The mec-8 gene of C. elegans encodes a protein with two RNA recognition motifs and regulates alternative splicing of unc-52 transcripts. , 1996, Development.

[45]  John M. Whitelock,et al.  The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*) , 1996, The Journal of Biological Chemistry.

[46]  A. Ljubimov,et al.  Antibody mapping and tissue localization of globular and cysteine-rich regions of perlecan domain III. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  Richard L. Stevens,et al.  Packaging of Proteases and Proteoglycans in the Granules of Mast Cells and Other Hematopoietic Cells , 1995, The Journal of Biological Chemistry.

[48]  G. Nilsson,et al.  Phenotypic Characterization of the Human Mast‐Cell Line HMC‐1 , 1994, Scandinavian journal of immunology.

[49]  R. Iozzo,et al.  Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[50]  R. Iozzo,et al.  Structural characterization of the complete human perlecan gene and its promoter. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[51]  G. R. Dodge,et al.  Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. , 1992, The Journal of biological chemistry.

[52]  D. Metcalfe,et al.  Murine mast cells synthesize basement membrane components. A potential role in early fibrosis. , 1991, The Journal of clinical investigation.

[53]  G. Bruns,et al.  Isolation and characterization of a cDNA that encodes the peptide core of the secretory granule proteoglycan of human promyelocytic leukemia HL-60 cells. , 1988, The Journal of biological chemistry.

[54]  D. Metcalfe,et al.  Identification of chondroitin sulfate E in human lung mast cells. , 1988, Journal of immunology.

[55]  M. Ligumsky,et al.  Human gastric mucosal mast cells are chondroitin sulphate E-containing mast cells. , 1987, Immunology.

[56]  K. Austen,et al.  Secretory granules of heparin-containing rat serosal mast cells also possess highly sulfated chondroitin sulfate proteoglycans. , 1986, The Journal of biological chemistry.

[57]  K. Austen,et al.  Coculture of interleukin 3-dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. Seldin,et al.  Purification and characterization of protease-resistant secretory granule proteoglycans containing chondroitin sulfate di-B and heparin-like glycosaminoglycans from rat basophilic leukemia cells. , 1985, The Journal of biological chemistry.

[59]  R. Clark,et al.  Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? , 1985, Annals of internal medicine.

[60]  J. Bienenstock,et al.  Mast cell heterogeneity and hyperplasia in bleomycin-induced pulmonary fibrosis of rats. , 1984, The American review of respiratory disease.

[61]  B. Caterson,et al.  Identification of a monoclonal antibody that specifically recognizes corneal and skeletal keratan sulfate. Monoclonal antibodies to cartilage proteoglycan. , 1983, The Journal of biological chemistry.